Tocilizumab Biosimilar, Anti-human IL-6R Antibody | Catalog C032P

Tocilizumab Biosimilar, Human IL-6R Monoclonal Antibody. The research grade tocilizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

Product Specifications

Catalog No.	C032P
Product Name	Tocilizumab Biosimilar, Human IL-6R Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Interleukin 6, IL-6, IL6, BSF2, HGF, HSF, IFNB2, BSF-2, CDF, IFN-beta-2, Interleukin 6 receptor, CD126, Cluster of Differentiation 126, IL-6R-1, IL-6RA, IL6Q, IL6RA, IL6RQ, gp80
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Humanized IgG1.
Source/Host	Produced in mammalian cells.
Specificity	Specifically binds to the human interleukin-6 receptor (IL-6R).

Properties & Storage

Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by tocilizumab.
Formulation	0.2 µM filtered solution, pH 6.5, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Tocilizumab biosimilar uses the same protein sequences as the therapeutic antibody tocilizumab. Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.

Interleukin 6 (IL-6) is a pro-inflammatory cytokine produced by cells including T-cells, B-cells, lymphocytes, monocytes, and fibroblasts. IL-6 rapidly induces C-reactive protein, serum amyloid A, fibrinogen, haptoglobin, and alpha-1-antichymotrypsin while inhibiting production of fibronectin, albumin, and transferrin. IL-6 also induces antibody production, induces cytotoxic T-cell differentiation, and inhibits regulatory T-cell differentiation. Tocilizumab binds soluble and membrane bound IL-6 receptors, preventing IL-6 mediated inflammation.